DLL3 CAR-T Therapy Targeting Brain Tumors

The purpose of this study is to assess the feasibility, safety and efficacy of Delta-like ligand 3 (DLL3)-specific CAR-T cell therapy in patients with DLL3 positive brain tumors including glioblastomas and diffused intrinsic pontine or midline gliomas (DIPG or DMG). Another goal of the study is to learn more about the function of the anti-DLL3 CAR-T cells and their persistency in patients.

NCT Number	NCT07180927
Lead Sponsor	Shenzhen Geno-Immune Medical Institute
Conditions	Glioblastoma of Cerebellum
Enrollment	30 participants
Start Date	2025-09-10
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-09-30 (estimated)
Updated on ClinicalTrials.gov	2025-09-18